Seres Therapeutics, Inc. (MCRB)
1.43
+0.02
(+1.42%)
USD |
NASDAQ |
Nov 18, 16:00
1.43
0.00 (0.00%)
After-Hours: 20:00
Seres Therapeutics Enterprise Value : 32.41M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 32.41M |
| November 16, 2026 | 32.41M |
| November 13, 2026 | 32.31M |
| November 12, 2026 | 32.41M |
| November 11, 2026 | 33.32M |
| November 10, 2026 | 33.92M |
| November 09, 2026 | 35.33M |
| November 06, 2026 | 38.14M |
| November 05, 2026 | 39.25M |
| November 04, 2026 | 39.25M |
| November 03, 2026 | 37.94M |
| November 02, 2026 | 36.63M |
| October 30, 2026 | 36.03M |
| October 29, 2026 | 37.84M |
| October 28, 2026 | 36.23M |
| October 27, 2026 | 36.33M |
| October 26, 2026 | 38.14M |
| October 23, 2026 | 39.25M |
| October 22, 2026 | 39.65M |
| October 21, 2026 | 41.36M |
| October 20, 2026 | 41.46M |
| October 19, 2026 | 42.56M |
| October 16, 2026 | 42.97M |
| October 15, 2026 | 43.67M |
| October 14, 2026 | 42.56M |
| Date | Value |
|---|---|
| October 13, 2026 | 43.67M |
| October 12, 2026 | 45.18M |
| October 09, 2026 | 45.48M |
| October 08, 2026 | 44.67M |
| October 07, 2026 | 45.58M |
| October 06, 2026 | 47.39M |
| October 05, 2026 | 46.89M |
| October 02, 2026 | 47.79M |
| October 01, 2026 | 47.69M |
| September 30, 2026 | 51.91M |
| September 29, 2026 | 75.25M |
| September 28, 2026 | 75.64M |
| September 25, 2026 | 75.64M |
| September 24, 2026 | 76.63M |
| September 23, 2026 | 78.30M |
| September 22, 2026 | 80.56M |
| September 21, 2026 | 81.05M |
| September 18, 2026 | 80.36M |
| September 17, 2026 | 81.34M |
| September 16, 2026 | 82.42M |
| September 15, 2026 | 86.26M |
| September 14, 2026 | 87.53M |
| September 11, 2026 | 90.29M |
| September 10, 2026 | 91.17M |
| September 09, 2026 | 92.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 464.42M |
| Amgen, Inc. | 288.51B |
| Anika Therapeutics, Inc. | 153.30M |
| BioCryst Pharmaceuticals, Inc. | 2.374B |
| Imunon, Inc. | 6.700M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.29M |
| Revenue (Quarterly) | 0.593M |
| Total Expenses (Quarterly) | 16.88M |
| EPS Diluted (Quarterly) | -1.632 |
| Gross Profit Margin (Quarterly) | 18.89% |
| Profit Margin (Quarterly) | -2.75K% |
| Earnings Yield | -338.8% |
| Normalized Earnings Yield | -275.97 |